A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Bennett, Gayle ^a   Sadlier, Denise ^b   Doran, Peter P ^b   MacMathuna, Padraic ^a   Murray, David W ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN NET1; PROTEIN TSPAN1; RANTES; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SHORT HAIRPIN RNA; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; NET1 PROTEIN, HUMAN; ONCOPROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LENTIVIRINAE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; BIOSYNTHESIS; CANCER INVASION; CELL GROWTH; CELL MOTION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL CULTURE;

ADENOCARCINOMA; CELL GROWTH PROCESSES; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79351469473     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-50     Document Type: Article

References (54)

1. Aurello P, D'Angelo F, Rossi S, et al. Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg 2007, 73:359-66.
2. Saito H, Fukumoto Y, Osaki T, et al. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol 2008, 97:132-5. 10.1002/jso.20929, 17979134.
3. Kim YJ, Kim MA, Im SA, et al. Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. Cancer Invest 2008, 26:152-8. 10.1080/07357900701518909, 18259945.
4. Kouraklis G, Katsoulis IE, Theocharis S, et al. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?. Dig Dis Sci 2009, 54:1015-20. 10.1007/s10620-008-0464-y, 19058005.
5. Kim JS, Kim MA, Kim TM, et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 2009, 100:732-8. 10.1038/sj.bjc.6604936, 2653762, 19259093.
6. Leyden J, Murray D, Moss A, et al. NET1 and Myeov: computationally identified mediators of gastric cancer. Br J Cancer 2006, 94:1204-12. 10.1038/sj.bjc.6603054, 2361249, 16552434.
7. Murray D, Horgan G, Macmathuna P, et al. NET1-mediated RhoA activation facilitates LPA-induced cell migration and invasion in gastric cancer. Br J Cancer 2008, 99:1322-9. 10.1038/sj.bjc.6604688, 2570507, 18827818.
8. Hasegawa S, Furukawa Y, Li M, et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002, 62:7012-7.
9. Ji J, Chen X, Leung SY, et al. Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene 2002, 21:6549-56. 10.1038/sj.onc.1205829, 12226758.
10. Hippo Y, Taniguchi H, Tsutsumi S, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002, 62:233-40.
11. Meireles SI, Carvalho AF, Hirata R, et al. Differentially expressed genes in gastric tumors identified by cDNA array. Cancer Lett 2003, 190:199-211. 10.1016/S0304-3835(02)00587-6, 12565175.
12. Yu CD, Xu SH, Mou HZ, et al. Gene expression profile differences in gastric cancer, pericancerous epithelium and normal gastric mucosa by gene chip. World J Gastroenterol 2005, 11:2390-7.
13. Inoue H, Matsuyama A, Mimori K, et al. Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 2002, 8:3475-9.
14. Chen CN, Lin JJ, Chen JJ, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 2005, 23:7286-95. 10.1200/JCO.2004.00.2253, 16145069.
15. Kang HC, Kim IJ, Park JH, et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004, 10:272-84. 10.1158/1078-0432.CCR-1025-3, 14734480.
16. Kim HK, Choi IJ, Kim HS, et al. DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 2004, 316:781-9. 10.1016/j.bbrc.2004.02.109, 15033468.
17. Hofman VJ, Moreilhon C, Brest PD, et al. Gene expression profiling in human gastric mucosa infected with Helicobacter pylori. Mod Pathol 2007, 20:974-89. 10.1038/modpathol.3800930, 17643099.
18. Backert S, Gressmann H, Kwok T, et al. Gene expression and protein profiling of AGS gastric epithelial cells upon infection with Helicobacter pylori. Proteomics 2005, 5:3902-18. 10.1002/pmic.200401240, 16145711.
19. Chiou CC, Chan CC, Sheu DL, et al. Helicobacter pylori infection induced alteration of gene expression in human gastric cells. Gut 2001, 48:598-604. 10.1136/gut.48.5.598, 1728271, 11302954.
20. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006, 7:3. 10.1186/1471-2199-7-3, 1413964, 16448564.
21. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-64. 10.1093/biostatistics/4.2.249, 12925520.
22. Newton MA, Kendziorski CM, Richmond CS, et al. On differential variability of expression ratios: improving statistical inference about gene expression changes from microarray data. J Comput Biol 2001, 8:37-52. 10.1089/106652701300099074, 11339905.
23. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-8. 10.1073/pnas.95.25.14863, 24541, 9843981.
24. Kishino H, Waddell PJ. Correspondence analysis of genes and tissue types and finding genetic links from microarray data. Genome Inform Ser Workshop Genome Inform 2000, 11:83-95.
25. Fellenberg K, Hauser NC, Brors B, et al. Correspondence analysis applied to microarray data. Proc Natl Acad Sci USA 2001, 98:10781-6. 10.1073/pnas.181597298, 58552, 11535808.
26. Gutkind JS, Crespo P, Xu N, et al. The pathway connecting m2 receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. Life Sci 1997, 60:999-1006. 10.1016/S0024-3205(97)00040-4, 9121367.
27. Guo X, Stafford LJ, Bryan B, et al. A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration. J Biol Chem 2003, 278:13207-15. 10.1074/jbc.M208896200, 12547822.
28. Minard ME, Kim LS, Price JE, et al. The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 2004, 84:21-32. 10.1023/B:BREA.0000018421.31632.e6, 14999151.
29. Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis 2006, 23:301-13. 10.1007/s10585-006-9040-z, 17086355.
30. Habets GG, Scholtes EH, Zuydgeest D, et al. Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell 1994, 77:537-49. 10.1016/0092-8674(94)90216-X, 7999144.
31. Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 2006, 12:65-75. 10.1016/j.molmed.2005.12.001, 16406843.
32. Murph M, Tanaka T, Liu S, et al. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res 2006, 12:6598-602. 10.1158/1078-0432.CCR-06-1721, 17121877.
33. Ernst M, Najdovska M, Grail D, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008, 118:1727-38. 2323192, 18431520.
34. Regis G, Pensa S, Boselli D, et al. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008, 19:351-9. 10.1016/j.semcdb.2008.06.004, 18620071.
35. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-74. 10.1038/nm934, 14502282.
36. Torrero MN, Xia X, Henk W, et al. Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res 2006, 66:4461-7. 10.1158/0008-5472.CAN-05-3554, 16618773.
37. Mitas M, Almeida JS, Mikhitarian K, et al. Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res 2005, 11:2205-14. 10.1158/1078-0432.CCR-04-1091, 15788668.
38. Brabender J, Marjoram P, Salonga D, et al. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene 2004, 23:4780-8. 10.1038/sj.onc.1207663, 15107828.
39. Scholz CJ, Kurzeder C, Koretz K, et al. Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas. Cancer Lett 2009, 275:198-203. 10.1016/j.canlet.2008.10.014, 19017553.
40. Chen L, Li X, Wang GL, et al. Clinicopathological significance of overexpression of TSPAN1, Ki67 and CD34 in gastric carcinoma. Tumori 2008, 94:531-8.
41. Ma C, Rong Y, Radiloff DR, et al. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008, 22:308-21. 10.1101/gad.1632008, 2216691, 18245446.
42. Sugasawa H, Ichikura T, Kinoshita M, et al. gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 2008, 122:2535-41. 10.1002/ijc.23401, 18246596.
43. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-16. 10.1038/nrm1962, 16829981.
44. O'Dwyer PJ, Benson AB. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002, 29:10-7.
45. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787-99. 10.1200/JCO.2003.01.504, 12860957.
46. Shida D, Fang X, Kordula T, et al. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 2008, 68:6569-77. 10.1158/0008-5472.CAN-08-0411, 2763580, 18701480.
47. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001, 98:2598-603. 10.1073/pnas.051630998, 30184, 11226285.
48. Jaeckel EC, Raja S, Tan J, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001, 127:1253-9.
49. Tong BJ, Tan J, Tajeda L, et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2000, 2:483-90. 10.1038/sj.neo.7900119, 1508090, 11228540.
50. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev 2005, 16:407-20. 10.1016/j.cytogfr.2005.01.010, 15886048.
51. Durai R, Yang W, Gupta S, et al. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 2005, 20:203-20. 10.1007/s00384-004-0675-4, 15650828.
52. Matsubara J, Yamada Y, Nakajima TE, et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008, 74:76-83. 10.1159/000139127, 18544998.
53. Coronas S, Lagarrigue F, Ramel D, et al. Elevated levels of PtdIns5P in NPM-ALK transformed cells: implication of PIKfyve. Biochem Biophys Res Commun 2008, 372:351-5. 10.1016/j.bbrc.2008.05.062, 18501703.
54. Kim J, Jahng WJ, Di Vizio D, et al. The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Res 2007, 67:9229-37. 10.1158/0008-5472.CAN-07-1333, 17909029.